{"filings":[{"id":2105962,"accession_number":"0001551306-26-000135","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-08-06T20:10:16+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Progyny Q2 revenue $350.5M (+5.3% YoY), adjusted EBITDA $62.1M; FY revenue guidance $1.36B-$1.385B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $350.5M, up 5.3% YoY; gross margin 25.5% vs 23.7% prior year.","Net income $28.1M ($0.34 diluted EPS) vs $17.1M ($0.19); adjusted EPS $0.55 vs $0.48.","Adjusted EBITDA $62.1M (17.7% margin) vs $57.9M (17.4%).","FY2026 guidance: revenue $1.36B-$1.385B, adjusted EBITDA $233M-$240M, adjusted EPS $2.04-$2.10.","Repurchased 1.2M shares in Q2 for $31.5M; $142.5M remaining under $200M authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":678796,"accession_number":"0001551306-26-000109","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-05-27T13:13:46+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Progyny shareholders approve elimination of supermajority voting requirements","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Super majority amendments passed with >65M votes for, 357K against.","Charter and bylaw amendments effective May 21, 2026, removing supermajority to remove directors and amend bylaws.","All three Class I director nominees elected: Lloyd Dean, Kevin Gordon, Cheryl Scott.","Ratification of Ernst & Young as auditor for FY2026 approved with 71M votes for.","Advisory say-on-pay approved with 61.8M votes for vs 3.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":650877,"accession_number":"0001551306-26-000074","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-05-26T13:15:09+00:00","items":["8.01"],"status":"ready","headline":"Progyny board approves $200M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $200M of common stock, funded from available cash balances.","Repurchases may be made through open market transactions or Rule 10b5-1 plans.","Program may be suspended or discontinued at any time; no assurance on number or prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93581,"accession_number":"0001551306-26-000062","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Progyny Q1 rev $328.5M (+1.4%), adj EPS $0.50; guides FY rev $1.365-1.405B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $328.5M (+1.4% YoY); ex-lost client revenue grew 12.2%. Net income $24.2M ($0.29 diluted) vs $15.1M.","Gross margin improved to 25.3% from 23.4%; Adjusted EBITDA $56.6M (17.2% margin) vs $57.8M (17.8%).","Completed $200M buyback; repurchased 8.8M shares total. Board evaluating new program, decision by end of May.","Client count 595 (up 63 YoY); covered lives ~7.2M. ART cycles 15,647 vs 16,160 (transition impact).","FY 2026 guidance: rev $1.365-1.405B, adj EBITDA $232-244M, adj EPS $1.98-2.09. Q2: rev $342-355M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":328504000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105332,"accession_number":"0001551306-26-000040","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Progyny settles derivative suit over director pay; caps annual comp at $288k per director","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Derivative action challenged non-employee director compensation since 2020; settlement includes governance reforms.","New policy caps annual director awards at $48k cash and $240k equity, total $288k per director.","Committee chairs and lead independent director receive additional cash awards ($25k, $20k, $15k, $40k).","Plaintiff's counsel to receive $450,000 in fees/expenses from defendants/insurers, subject to court approval.","Settlement hearing set for May 28, 2026; reforms must be maintained for at least 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105331,"accession_number":"0001551306-26-000012","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Progyny Q4 revenue up 6.7% to $318.4M; guides FY2026 revenue $1.355B-$1.405B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $318.4M (+6.7% YoY); FY2025 revenue $1.2887B (+10% YoY); gross margin expanded to 24.1%.","Q4 net income $12.5M ($0.14 diluted EPS); adj. EPS $0.48; adj. EBITDA $51.4M (16.1% margin).","Full year operating cash flow record $210.2M; repurchased 3.3M shares in Q4, 6.5M total under $200M authorization.","FY2026 revenue guidance $1.355B-$1.405B; adj. EBITDA $224M-$239M; adj. EPS $1.83-$1.95.","Client count 555 as of Dec 2025 (up from 473); expects ~600 clients representing ~7.2M covered lives in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1288661000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105330,"accession_number":"0001551306-26-000009","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny expects Q4 2025 revenue, net income, Adj. EBITDA slightly above prior guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["CEO cites favorable Q4 member engagement vs. November guidance.","Expects Q4 revenue, net income and Adjusted EBITDA slightly above prior ranges.","Update excludes non-cash impacts from departure of President Michael Sturmer.","Presenting at 44th Annual JP Morgan Healthcare Conference on Jan 13, 2026.","No specific revised figures provided; guidance remains qualitative."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1288661000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121607,"accession_number":"0001551306-25-000218","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Progyny President Michael Sturmer to depart Dec 31, 2025; no successor named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President Michael Sturmer's employment ends Dec 31, 2025.","No successor named; company cites recent additions of CCO, CTO, COO, CPO.","Sturmer will serve as consultant through Dec 31, 2026 with $250k annual fee.","Vested options extended if consulting continues through June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121606,"accession_number":"0001551306-25-000186","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Progyny Q3 revenue $313.3M (+9.3% YoY), raises FY2025 guidance; board authorizes $200M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $313.3M (+9.3% YoY), net income $13.9M ($0.15 EPS), adj. EBITDA $55.0M (17.5% margin).","New clients: 80+ new, 900k new lives, ~100% retention for 2026.","FY2025 revenue guidance raised to $1.263-1.278B; adj. EBITDA $216-220M.","Board authorized up to $200M share repurchase program.","Record $156M operating cash flow in first nine months of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":970258000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138264,"accession_number":"0001551306-25-000161","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q2 revenue $332.9M (+9.5% YoY); raises FY2025 guidance on strong member engagement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $332.9M, up 9.5% YoY; ex-large-client transition revenue grew 18%.","Adjusted EBITDA $57.9M (17.4% margin); adjusted EPS $0.48 vs $0.43 prior year.","Raises FY2025 revenue guidance to $1.235B-$1.270B; adjusted EPS guidance to $1.70-$1.78.","Record H1 operating cash flow $105.3M; no debt; entered $200M revolver (undrawn).","Fertility clients grew to 542 from 463 YoY; ART cycles 16,938 (+8.8% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":656912000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138263,"accession_number":"0001551306-25-000153","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Progyny enters $200M credit facility; Q2 results expected slightly above guidance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $200M revolving credit facility maturing July 1, 2030; undrawn at closing.","Facility secured by substantially all assets; variable interest based on SOFR or base rate plus margin.","Q2 2025 revenue, Adjusted net income, and Adjusted EBITDA expected slightly above prior guidance.","Company has no planned use for facility; capital priorities (buybacks, product expansion, acquisitions) unchanged.","JPMorgan Chase Bank acts as administrative agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155718,"accession_number":"0001551306-25-000131","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Progyny shareholders reject advisory vote on executive compensation at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director nominees Norman Payson, Debra Morris, Elizabeth Bierbower elected with majority votes.","Ratification of Ernst & Young as independent auditor approved (75.2M for, 544k against).","Advisory say-on-pay proposal failed: 43.9M against vs 24.4M for; 7.3M broker non-votes.","88.4% of outstanding shares (75.7M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155717,"accession_number":"0001551306-25-000092","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q1 revenue $324M (+16.5% YoY), raises FY2025 guidance above prior outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $324.0M (+16.5% YoY); gross margin 23.4% vs 22.4% a year ago.","Adjusted EBITDA $57.8M (17.8% margin) vs $50.3M (18.1% margin) in Q1 2024.","Net income $15.1M ($0.17 EPS); adjusted EPS $0.48 vs $0.39 in prior year.","FY2025 revenue guidance raised to $1.185B-$1.235B; adjusted EBITDA guided $190M-$203M.","Fertility clients 532 (up from 451); ART cycles 16,160 (+9.2% YoY). Large client transition contributed $31.3M revenue in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":324038000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155716,"accession_number":"0001551306-25-000070","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Dr. Fred E. Cohen to leave Progyny board after 2025 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cohen notified Progyny on April 9, 2025 of his decision not to stand for reelection at the 2025 Annual Meeting.","Decision unrelated to any disagreement with the Company on operations, policies, or practices.","Cohen will continue serving as director through the end of his current term at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174208,"accession_number":"0001551306-25-000025","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K/A","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny reports Q4 revenue $298.4M (+10.6% YoY); FY2025 guidance $1.175-1.225B; corrects 2025 ART cycle outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 EPS); Adj. EBITDA $47.5M (15.9% margin).","FY2024 revenue $1.167B (+7.2%); net income $54.3M ($0.57 EPS); Adj. EBITDA $198.8M (17.0% margin).","FY2025 guidance: revenue $1.175-1.225B; Adj. EBITDA $188-201M; Adj. EPS $1.52-1.62.","Correction: 2025 ART cycle guidance revised to 61,600-64,300 from 59,350-61,850; no change to financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1167221000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174211,"accession_number":"0001551306-25-000022","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q4 rev $298.4M (+10.6%); large client non-renewal pressures 2025 guide of 1-5% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 diluted EPS) vs $13.5M ($0.13) prior year.","Adjusted Q4 EPS $0.42 vs $0.32 prior year; Adjusted EBITDA $47.5M (+10%).","Full year 2024 revenue $1,167.2M (+7.2%); net income $54.3M ($0.57) vs $62.0M ($0.62).","One large client did not renew for 2025; excluding it, 2024 revenue grew 8.5%; expects >530 clients in 2025.","FY2025 guidance: revenue $1.175B-$1.225B (1-5% growth), adjusted EBITDA $188M-$201M, adjusted EPS $1.52-$1.62."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1167221000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174210,"accession_number":"0001551306-25-000010","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Progyny appoints Debra Morris to board effective Jan 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Debra Morris appointed as Class III director, term expires at 2025 annual meeting.","Morris will serve on Compensation Committee and receives $40k annual cash retainer.","Initial grant of options to purchase 44,000 shares vesting over four years.","Morris is President of AccessHope, former CFO of Apria; also on boards of REXR and BTMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174209,"accession_number":"0001551306-25-000006","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny expects Q4 2024 revenue, net income, Adjusted EBITDA slightly above prior guidance","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company updates guidance at JPM Healthcare Conference; Q4 results expected slightly above November ranges.","Previous guidance assumed member activity flat to down vs Q3 2024; improved pacing drove the beat.","CEO Pete Anevski to present on Jan 14, 2025 at 7:30 a.m. PT; audiocast available on investor site.","No specific dollar amounts or revised ranges provided in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191141,"accession_number":"0001551306-24-000199","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q3 revenue up 2% to $286.6M, net income falls 34% to $10.4M; cuts FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $286.6M (+2% YoY); net income $10.4M ($0.11 diluted EPS) vs $15.9M ($0.16) in Q3 2023.","Adjusted EBITDA $46.5M (-7.1% YoY); margin 16.2% vs 17.8% a year ago.","Full-year 2024 revenue guidance lowered to $1.135-1.150B; adjusted EBITDA guidance $189-194M.","New sales season adds 80+ clients, 1.1M new covered lives; also selected by two health plans as preferred partner.","Q3 utilization rate lower than expected; members took longer to progress, consuming fewer treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":868790000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207620,"accession_number":"0001551306-24-000183","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Progyny loses client representing ~12-13% of revenue; termination effective Jan 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Client with ~670k members exercised 90-day termination option; no disputes or service issues cited.","Client comprised 12% of H1 2024 revenue and 13% of FY 2023 revenue; no other client > single-digit percentage.","No adverse impact expected on FY 2024 financial results; services continue through end of 2024.","Company expects overall member count to increase in 2025 despite the loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207619,"accession_number":"0001551306-24-000163","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Progyny holds inaugural Investor Day; presentation furnished without new financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Hosted first-ever Investor Day on August 12, 2024; webcast replay available on website.","Exhibit 99.1 contains only title slides and safe harbor language; no specific financial targets or operational metrics disclosed in filing.","No changes to guidance, dividend, or executive leadership announced in the 8-K or exhibit.","Event is procedural; material content, if any, would be in the full presentation not fully included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207618,"accession_number":"0001551306-24-000152","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q2 beats on adjusted EBITDA but cuts full-year guidance on lower revenue per member","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $304.1M (+8.8% YoY), record Adj. EBITDA $54.5M (+15% YoY), margin 17.9%.","Net income $16.5M ($0.17 diluted EPS); Adj. EPS $0.43 vs $0.36 a year ago.","Board authorized $100M stock buyback; 6.8M shares repurchased YTD under prior programs.","Full-year 2024 revenue guidance revised to $1.165-1.20B (7-10% growth); Adj. EBITDA $199-209M.","Q3 2024 revenue guidance $290-303M; Adj. EBITDA $47.5-51.0M; citing lower revenue per utilizing member."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":582165000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225071,"accession_number":"0001551306-24-000128","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Progyny stockholders re-elect directors, ratify EY, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Anevski, Holstein, Park, Schlanger with 62M+ votes for each; broker non-votes 5,878,612.","Ratified Ernst & Young as independent auditor for fiscal 2024: 89.5M for, 331K against, 163K abstentions.","Advisory say-on-pay approved: 82.1M for, 1.9M against, 134.5K abstentions.","Turnout: 90,037,222 shares (93.68% of eligible) voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225070,"accession_number":"0001551306-24-000107","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Progyny board authorizes $100M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved a new $100M share repurchase program on May 22, 2024.","Follows an earlier program announced Feb 29, 2024; funded from available cash.","Repurchases may be via open market or 10b5-1 plans; program can be suspended anytime.","No assurances on number of shares or prices at which purchases will be made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225069,"accession_number":"0001551306-24-000096","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q1 revenue up 7.6% to $278M; cuts FY revenue guidance to $1.23-1.27B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $278.1M (+7.6% YoY), net income $16.9M ($0.17 diluted EPS), adjusted EPS $0.39.","Adjusted EBITDA $50.3M (+8%), margin 18.1% vs 17.9% prior year period.","FY 2024 revenue guidance lowered to $1.23-1.27B (from prior $1.27-1.31B) citing lower March utilization.","Repurchased 723,577 shares for $26.4M in Q1; $32M remains under $100M buyback authorization.","Clients grew 19% YoY to 451; ART cycles increased 12.4% to 14,802."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":278078000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244294,"accession_number":"0001551306-24-000018","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny reports record FY23 revenue $1.09B (+38%); guides FY24 $1.285-$1.315B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 revenue $1,088.6M (+38% YoY); net income $62.0M ($0.62 diluted EPS), adj. EBITDA $187.1M (+49%).","Q4 revenue $269.9M (+26%); net income $13.5M ($0.13 EPS); adj. EBITDA $43.2M (+31%).","Clients grew to 392 as of Dec 31, 2023, from 288 a year earlier; expects >460 clients in 2024.","FY24 revenue guidance $1.285-$1.315B (+18-21%), adj. EBITDA $224-$232M, adj. EPS $1.54-$1.59.","Q1 2024 revenue guided $285-$292M (+10-13%); cites ~$15M headwind from short-term treatment mix shift."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1088598000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261707,"accession_number":"0001551306-23-000093","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q3 rev $280.9M (+37% YoY), net income $15.9M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record quarterly revenue $280.9M, up 37% YoY; net income $15.9M ($0.16 diluted EPS).","Adjusted EBITDA $50.0M (+43% YoY), margin 17.8% vs 17.0% prior year.","Added 1.3M new covered lives in selling season; clients at 392 vs 282 a year ago; ~100% retention.","Raised FY 2023 revenue guidance to $1,087-1,095M and Adj. EBITDA to $186-188.5M.","First federal government plan win with ~300k covered lives; expects lower margin from this population in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":280891000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278922,"accession_number":"0001551306-23-000060","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q2 revenue $279.4M (+43% YoY); raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $279.4M (+43% YoY); net income $15.0M ($0.15 diluted EPS) vs $8.8M ($0.09) YoY.","Adjusted EBITDA $47.5M (+44% YoY); record operating cash flow $76.0M, helped by new pharmacy partner agreements.","Clients grew to 384 (from 273); ART cycles 14,771 (+42% YoY); utilization rates improved.","FY 2023 revenue guidance raised to $1,075-1,090M (37-39% growth); adj EBITDA guided $183-187.5M.","Q3 2023 revenue guided $268-273M; adj EBITDA $44.7-46.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":330.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":279373000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297207,"accession_number":"0001551306-23-000052","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Progyny shareholders reject advisory say-on-pay vote at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Lloyd Dean, Kevin Gordon, Cheryl Scott elected with 78.8M, 55.1M, 56.3M votes for, respectively.","Ernst & Young LLP ratified as auditor for FY 2023 with 88.4M votes for, 0.3M against.","Non-binding advisory vote on executive compensation failed: 27.1M for, 55.8M against, 0.06M abstentions.","All results reported from the May 24, 2023 annual meeting of stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297206,"accession_number":"0001551306-23-000045","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q1 revenue $258.4M (+50% YoY); raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $17.7M ($0.18 diluted EPS) vs $5.0M ($0.05) in Q1 2022.","Adjusted EBITDA $46.4M (+87% YoY); margin expanded 350 bps to 17.9%.","FY2023 revenue guidance raised to $1.04-1.065B from prior range.","Clients grew to 379 (from 264) and covered lives to 5.34M (+36% YoY).","Fertility revenue $157.1M (+42%); pharmacy revenue $101.2M (+65%)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":258394000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297205,"accession_number":"0001551306-23-000028","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-04-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Progyny reaffirms strong utilization, 5.4M covered lives, new channel partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Affirms strong utilization for fertility services across >370 clients, representing ~5.4 million covered lives.","Reports strong interest from prospective clients as benefits selling season gets underway.","Recently disclosed channel partner relationships with Children's Hospital Association and Evernorth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317582,"accession_number":"0001551306-23-000026","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Progyny discloses less than 2% of cash held at SVB, considers exposure immaterial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Less than 2% of cash, cash equivalents, and marketable securities as of Dec 31, 2022 were at risk from SVB receivership.","Company states risk exposure to Silicon Valley Bank is immaterial.","Disclosure made on March 13, 2023 via Form 8-K Item 7.01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317581,"accession_number":"0001551306-23-000009","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q4 revenue $214.3M (+68% YoY); FY2022 revenue $786.9M (+57%); guides FY2023 above $1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $214.3M, up 68% YoY; gross profit $44.5M (+77%); net income $3.4M ($0.03 diluted EPS).","Full year 2022 revenue $786.9M, up 57% YoY; net income $30.4M ($0.30 diluted EPS); Adjusted EBITDA $125.7M (+87%).","FY2023 guidance: revenue $1,000M-$1,030M (27-31% growth); Adjusted EBITDA $166M-$174M; net income $27.0M-$32.7M.","Q1 2023 guidance: revenue $245M-$250M (42-45% growth); Adjusted EBITDA $41.5M-$44.0M.","Clients grew to 288 from 191 a year ago; no debt; working capital $274.3M; operating cash flow $80.4M in FY2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":786913000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317580,"accession_number":"0001551306-23-000005","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny reaffirms FY2022 high-end guidance; expects record Q4 operating cash flow ~$50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 and FY2022 revenue, net income, Adj. EBITDA expected at or near high-end of guidance issued Nov 28, 2022.","Record Q4 operating cash flow of ~$50M; full-year ~$79M, reflecting high capital efficiency.","More than 370 clients and 5.4 million covered lives for 2023; substantially all new clients already launched.","Record new client wins in 2022; over 25% of existing clients expanded relationships despite macro environment.","Early 2023 selling season activity very encouraging; family building benefits remain top employer priority."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335812,"accession_number":"0001551306-22-000038","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-11-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Progyny raises FY2022 guidance after Menopur supply resumes; revenue now $781.5-$786.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue guidance raised to $781.5-786.5M (56-57% YoY growth) for full year 2022.","Net income guided to $28.5-29.5M ($0.28-0.29 diluted EPS); adjusted EBITDA $124-125.5M.","Q4 2022 revenue projected at $208.9-213.9M (64-68% growth); net income $1.5-2.5M.","Guidance increase due to resumed shipments of Menopur, a key fertility medication, after industry-wide shortage.","Company now serves >370 clients representing 5.4 million members as it enters 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335811,"accession_number":"0001551306-22-000028","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q3 revenue $205.4M (+68% YoY); raises FY2022 revenue guidance to $775-785M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $205.4M (+68% YoY); net income $13.2M ($0.13 EPS) vs $16.8M ($0.17) year ago.","Adjusted EBITDA $35.0M (+112% YoY); margin 17.0% vs 13.5%.","Record 105 new client commitments in selling season; near 100% retention; anticipates 370 clients and 5.4M covered lives by 2023.","Raises full-year 2022 revenue guidance to $775-785M (55-57% growth); Q4 revenue guided $202.4-212.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":205371000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353240,"accession_number":"0001551306-22-000023","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Progyny appoints Lloyd H. Dean to board of directors, expanding board to ten","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10; Dean appointed as Class I director effective Aug 30, 2022.","Dean is CEO Emeritus of CommonSpirit Health and former CEO of Dignity Health; also serves on McDonald's board.","Initial option grant of 44,000 shares vesting over 4 years; annual cash retainer of $40,000.","Dean appointed to the Nominating and Corporate Governance Committee.","No material interest in any related-party transaction; standard indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353239,"accession_number":"0001551306-22-000012","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q2 revenue $195M (+52% YoY); raises FY2022 guidance lower end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $195M vs $128.7M YoY; net income $8.8M ($0.09 diluted EPS) vs $18.7M ($0.19).","Adjusted EBITDA $32.9M (+78% YoY); margin 16.9% (+250 bps YoY).","Total clients 273 as of June 30, 2022, up from 182 a year ago.","Full-year revenue guidance raised to $750-775M; Adj. EBITDA guidance $114-122M.","Operating cash flow $19.2M vs -$7.5M YoY; no debt, $122.4M cash and marketable securities."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":195004000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370931,"accession_number":"0001558370-22-009468","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Progyny shareholders elect three Class III directors at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Fred E. Cohen elected with 54.8M for, 24.0M withheld; broker non-votes 4.9M.","Dr. Norman Payson elected with 47.9M for, 30.9M withheld.","Dr. Beth Seidenberg elected with 54.9M for, 23.9M withheld.","Ratified Ernst & Young as FY2022 auditor: 83.4M for, 252.5K against.","Advisory vote on executive compensation approved: 77.7M for, 1.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370930,"accession_number":"0001558370-22-007387","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q1 revenue $172.2M (+41%); net income $5.0M; raises FY22 guidance lower end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $172.2M (+41% YoY); gross profit $32.9M (+14%); net income $5.0M ($0.05 EPS) vs $15.2M prior year.","Adjusted EBITDA $24.8M (+44%); margin 14.4% vs 14.1%.","Clients grew to 264 from 179 a year ago; avg members 3.93M.","Full-year revenue guidance narrowed to $735M-$775M; Q2 guidance $188M-$193M (46-50% growth).","Cash used by ops $11.3M vs +$0.5M; cash/securities $105.7M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":172217000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370929,"accession_number":"0001558370-22-005088","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Malissia Clinton resigns from Progyny Board effective April 18, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Malissia Clinton resigned from the Board and Nominating and Corporate Governance Committee, effective April 18, 2022.","Resignation due to new outside restrictions on board commitments, not due to any disagreement with the company.","No successor or replacement board member announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389959,"accession_number":"0001558370-22-002357","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny reports FY2021 revenue $500.6M (+45% YoY); guides FY2022 rev $730-775M (+50% midpt)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue $500.6M (45% growth); net income $65.8M ($0.66 EPS); adj. EBITDA $67.3M (13.5% margin, +410bps).","Q4 2021 revenue $127.6M (27% growth); adj. EBITDA $15.1M (28% growth); gross margin excl. SBC improved 170bps to 23.4%.","Clients grew to 191 from 135; ART cycles increased 50% to 28,413; average members 2.81M (+28%).","FY2022 guidance: rev $730-775M (46-55% growth); adj. EBITDA $110-122M; net income $(1.4)M to $7.0M.","Q1 2022 guidance: rev $165-170M (35-39% growth); adj. EBITDA $23.5-24.5M; net loss $(2.1)-$(1.4)M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":500621000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407928,"accession_number":"0001558370-21-014614","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Progyny Reports Q3 2021 Revenue of $122.3M, Appoints Pete Anevski as CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2021 revenue $122.3M (+24% YoY), net income $16.8M vs $4.8M in prior year.","Added 85+ new clients for 2022, representing approximately 1.2M new covered lives.","David Schlanger to become Executive Chairman; Pete Anevski succeeds as CEO effective Jan 1, 2022.","Full-year 2021 revenue guidance raised to $507M-$514M, growth of 47-49%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":122284000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426944,"accession_number":"0001558370-21-010564","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q2 revenue surges 99% to $128.7M; net income of $18.7M vs loss a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net income of $18.7M ($0.19 diluted EPS) vs net loss of $1.1M in Q2 2020","Adjusted EBITDA of $18.5M (14.4% margin) vs $3.8M (5.9% margin) a year ago","Client count rose to 182 from 134; ART cycles more than doubled to 7,340","Q3 2021 revenue guidance $121M-$130M; full year revenue guidance $510M-$530M","Management notes strong sales momentum but sees short-term utilization dip in July/August"],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":128651000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}